1. Castillo, JJ, Winer, ES, Stachurski, D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51(11):2047-2053.
Google Scholar | Crossref | Medline2. Castillo, JJ, Reagan, JL. Plasmablastic lymphoma: a systematic review. Sci World J. 2011;11:687-696.
Google Scholar | Crossref3. Morscio, J, Dierickx, D, Nijs, J, Verhoef, G, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients. Am J Surg Pathol. 2014;38(7):875-886.
Google Scholar | Crossref | Medline4. Castillo, JJ, Bibas, M, Miranda, RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323-2330.
Google Scholar | Crossref | Medline5. Castillo, JJ, Winer, ES, Stachurski, D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuke. 2011;11(2):185-189.
Google Scholar | Crossref6. Delecluse, HJ, Anagnostopoulos, I, Dallenbach, F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413-1420.
Google Scholar | Crossref | Medline7. Belli, S, Yildirim, M, Eroglu, S, Emre, FK. Single-sided sinonasal mass: a retrospective study. North Clin Istanbul. 2018;5(2):139-143.
Google Scholar | Medline8. Wynn, R, Har-El, G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811-813.
Google Scholar | Crossref | Medline9. Nhlonzi, G, Mwazha, A, Naicker, N. Plasmablastic neoplasms with unusual histomorphology: a report of two cases. Hum Pathol Case Report. 2020;22(200441):2214-3300.
Google Scholar10. Shannon-Lowe, C, Rickinson, AB, Bell, AI. Epstein-Barr virus-associated lymphomas. Phil Trans Biol Sci. 2017;372(1732):20160271.
Google Scholar | Crossref | Medline11. Makady, NF, Ramzy, D, Ghaly, R, Abdel-Malek, RR, Shohdy, KS. The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes. Clin Lymphoma Myeloma Leuke. 2021;21(3):e255-e263.
Google Scholar | Crossref12. Rudresha, AH, Lakshmaiah, KC, Agarwal, A, et al. Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: experience at a regional cancer centre in India. South Asia J Cancer. 2017;6(2):69-71.
Google Scholar | Crossref | Medline13. Witte, HM, Künstner, A, Hertel, N, et al. Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. Blood Adv. 2021. [published online ahead of print, 2021 Oct 29]. doi:10.1182/bloodadvances.2021005486.
Google Scholar | Crossref14. Ramis-Zaldivar, JE, Gonzalez-Farre, B, Nicolae, A, et al. MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106(10):2682-2693.
Google Scholar | Crossref | Medline15. Frontzek, F, Staiger, AM, Zapukhlyak, M, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12(1):5183.
Google Scholar | Crossref | Medline16. Shaim, H, Estrov, Z, Harris, D, et al. The CXCR4-STAT3-IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia and is modulated by lenalidomide. Front Immunol. 2018;8:1773.
Google Scholar | Crossref | Medline17. Makady, NF, Ramzy, D, Ghaly, R, Abdel-Malek, RR, Shohdy, KS. The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes. Clin Lymphoma, Myeloma & Leukemia. 2021;21(3):e255-e263. doi:10.1016/j.clml.2020.11.025.
Google Scholar | Crossref | Medline